A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2023-07-25
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-24 (study day 85); relationship: not assessed
mild
assessed
Grade 1 Vomiting — outcome: UNKNOWN; onset 2024-02-18 (study day 202); relationship: not assessed
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-06-16 (study day 321); relationship: not assessed
Data queries
No data queries.